Guldeniz Doganay
Cardiovascular Disease · Brooklyn, NYNPI 1114023918
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $517 and has fallen 58.1% since, to $216 in 2022. That places this record below the midpoint for cardiovascular disease clinicians in NY, where the typical reported total is $1,486.
Across 63 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$204
- Bayer$142
- Merck$103
- Pfizer$100
- Esperion Therapeutics, Inc.$66
- Novo Nordisk$65
- plus $508 from 14 others
What the payments were for
- Food & beverage$1,189100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 12 | $204 |
| Bayer | 6 | $142 |
| Merck | 6 | $103 |
| Pfizer | 6 | $100 |
| Esperion Therapeutics, Inc. | 3 | $66 |
| Novo Nordisk | 3 | $65 |
| Abbott | 3 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Bardy Diagnostics, Inc. | 2 | $52 |
| Johnson & Johnson | 3 | $48 |
| Novartis | 2 | $47 |
| Boehringer Ingelheim | 2 | $43 |
| AstraZeneca | 2 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Lilly USA, LLC | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Amgen | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
How this compares
$1,189 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Brooklyn
- Ronald WhartonBrooklyn$426K
- Warren WexelmanBrooklyn$396K
- Ozgen DoganBrooklyn$290K
- Sergey AyzenbergBrooklyn$157K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.